In conclusion, given FABP7’s dual role in transporting both DHA-derived mediators and cannabinoids, it emerges as a novel therapeutic target bridging dietary fatty acid interventions and modulation of cannabinoid signaling pathways to mitigate the neuroinflammation of AD. Here, FABP7 is linked to Alzheimer disease.